IXICO to present three posters at California Alzheimer's conference

The AI data analytics group specialises in aiding neuroscience clinical drug development


IXICO PLC (LON:IXI) said it is delivering three poster presentations at a California conference on Alzheimer’s disease.

The AI data analytics group, which specialises in aiding neuroscience clinical drug development, will showcase its work in classifying sufferers of the disease.

It will also outline advances in measuring brain volume change and the work it has done using diffusion MRI analysis to assess the degenerative condition.

The posters will be displayed in the Indigo Foyer on Thursday (December 5) at the Hilton Bayfront, San Diego, which is hosting the 2019 Clinical Trials on Alzheimer's Disease Congress (CTAD).

IXICO’s chief products officer, Alison Howie, said: "We are delighted to be presenting three abstracts at this year's CTAD Congress, demonstrating IXICO's expertise in advancing data analytics to deliver intelligent insights which are vital in ensuring the successful progression of clinical trials.

“IXICO's key mission is the development of data analytics to speed the advancement of effective treatments for neurodegenerative diseases, like Alzheimer's disease, that tragically affect so many patients worldwide."

For more details on the posters and information on the event, click here.

Quick facts: IXICO PLC

Price: 83.25 GBX

Market: AIM
Market Cap: £39.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...



IXICO PLC reports first year of profitability 'well ahead of expectations'

IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM . For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...

on 4/12/19


Result of AGM

4 days, 13 hours ago

Director/PDMR Shareholding

6 days, 19 hours ago

Issue of Equity

1 week, 2 days ago

PDMR share sale

on 9/12/19

PDMR share purchase

on 9/12/19

2 min read